Funding neglected disease R&D beneficial to Europe, developing countries, report says

In this bulletin from Science Business, Karen Hoehn, vice executive director and director of international affairs at the German Foundation for World Population, highlights "a study by the independent research group Policy Cures, 'Saving Lives and Creating Impact: E.U. Investment in Poverty-Related and Neglected Disease,'" which she says "confirms that European funding for global health research and development [R&D] through the new E.U. Framework Programme for Research and Innovation, Horizon 2020, will have a direct benefit on both developing countries and on Europe." She writes that R&D funding for poverty-related and neglected diseases helps create jobs, discover new treatments, and "generates a net benefit to Europe's economy." Hoehn notes that "[a]ll E.U. funding for research and development into poverty-related and neglected diseases will be coordinated through Horizon 2020," and adds, "Cutting global health funding in Horizon 2020 would be detrimental to the European economy, as well as to developing countries" (9/27).